Stock GKOS GLAUKOS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Glaukos Corporation

Equities

GKOS

US3773221029

Market Closed - Nyse
Other stock markets
 16:00:02 2024-05-08 EDT 		5-day change 1st Jan Change
106.9 USD -0.99% Intraday chart for Glaukos Corporation +8.09% +34.49%
05-06 Jefferies Upgrades Glaukos to Buy From Hold, Raises Price Target to $125 From $84 MT
05-02 Needham Adjusts Price Target on Glaukos to $113 From $108, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Truist Raises Glaukos' PT to $125 From $120 After 'Solid' Q1 Beat, Keeps Buy Rating
MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Revenue $85.6M, vs. Street Est of $79.7M
MT
Glaukos Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Rise Wednesday Afternoon
MT
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services
MT
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)
CI
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase
MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M
MT
Glaukos Corporation Reaffirms Financial Guidance for 2024
CI
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise
MT
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024
CI
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR
MT
Glaukos Says FDA Approves New Drug Application for iDose TR
MT
Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024
CI
Glaukos Corporation Announces FDA Approval of iDose® TR (travoprost intracameral implant)
CI
Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $78M, vs. Street Est of $75.3M
MT
Glaukos Corporation Revises Consolidated Revenue Guidance for the Year 2023
CI
Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Revenue $80.4M, vs. Street Est of $74.7M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GKOS Stock
  4. News Glaukos Corporation
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW